When you hear the words Alzheimer's disease, what do you think of? The truth is, the picture most of us have of the disease is incomplete. Alzheimer's disease doesn't start when someone starts to lose their memory. It actually starts years – sometimes decades – earlier. The Rethinking Alzheimer's Disease Podcast is an engaging, narrative-style podcast miniseries for those curious or motivated to learn about Alzheimer’s disease. Perhaps you have a family member with Alzheimer’s disease, or ca ...
…
continue reading
PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!
Player FM 앱으로 오프라인으로 전환하세요!
Stanley C. Jordan, MD, FASN, FAST - Visualizing Progress in the Treatment of Chronic Active Antibody-Mediated Rejection: A Closer Look at the Clinical Potential of Targeting IL-6 to Improve Outcomes in the Kidney Transplant Setting
Manage episode 364925068 series 1118501
PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Go online to PeerView.com/RBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated video activity, Dr. Stanley C. Jordan discusses the rationale for targeting IL-6 in chronic active antibody-mediated rejection, as well as the use of anti–IL-6 agents for the treatment of chronic active antibody-mediated rejection in the kidney transplant setting. Upon completion of this activity, participants should be better able to: Utilize the Banff classification to characterize the nature and extent of kidney transplant rejection in order to guide treatment; Discuss the rationale for targeting IL-6 as a therapeutic approach to chronic active antibody-mediated rejection in kidney transplant recipients; and Evaluate the efficacy, safety, and clinical potential of anti–IL-6 agents currently in development for the treatment of chronic active antibody-mediated rejection in the kidney transplant setting
…
continue reading
107 에피소드
Stanley C. Jordan, MD, FASN, FAST - Visualizing Progress in the Treatment of Chronic Active Antibody-Mediated Rejection: A Closer Look at the Clinical Potential of Targeting IL-6 to Improve Outcomes in the Kidney Transplant Setting
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Manage episode 364925068 series 1118501
PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Go online to PeerView.com/RBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated video activity, Dr. Stanley C. Jordan discusses the rationale for targeting IL-6 in chronic active antibody-mediated rejection, as well as the use of anti–IL-6 agents for the treatment of chronic active antibody-mediated rejection in the kidney transplant setting. Upon completion of this activity, participants should be better able to: Utilize the Banff classification to characterize the nature and extent of kidney transplant rejection in order to guide treatment; Discuss the rationale for targeting IL-6 as a therapeutic approach to chronic active antibody-mediated rejection in kidney transplant recipients; and Evaluate the efficacy, safety, and clinical potential of anti–IL-6 agents currently in development for the treatment of chronic active antibody-mediated rejection in the kidney transplant setting
…
continue reading
107 에피소드
모든 에피소드
×플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.